Lepu Biopharma Valuation

Is 2157 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2157 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2157's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2157's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2157?

Key metric: As 2157 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2157. This is calculated by dividing 2157's market cap by their current revenue.
What is 2157's PS Ratio?
PS Ratio	22.3x
Sales	CN¥205.08m
Market Cap	CN¥4.56b

2157 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	23.1x
Enterprise Value/EBITDA	-12.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 2157's PS Ratio compare to its peers?

The above table shows the PS ratio for 2157 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.9x
6955 Shandong Boan Biotechnology	5.5x	29.0%	HK$4.2b
775 CK Life Sciences Int'l. (Holdings)	0.8x	n/a	HK$4.2b
9966 Alphamab Oncology	14.2x	39.4%	HK$3.9b
6660 AIM Vaccine	7x	n/a	HK$8.9b
2157 Lepu Biopharma	22.3x	65.6%	HK$4.9b

Price-To-Sales vs Peers: 2157 is expensive based on its Price-To-Sales Ratio (22.3x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does 2157's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
6826 Shanghai Haohai Biological Technology	2.1x	11.8%	US$1.82b
1530 3SBio	1.5x	9.3%	US$1.70b
2696 Shanghai Henlius Biotech	1.8x	10.1%	US$1.44b
775 CK Life Sciences Int'l. (Holdings)	0.8x	n/a	US$543.37m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 2157 is expensive based on its Price-To-Sales Ratio (22.3x) compared to the Hong Kong Biotechs industry average (11.4x).

Price to Sales Ratio vs Fair Ratio

What is 2157's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2157 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	22.3x
Fair PS Ratio	23x

Price-To-Sales vs Fair Ratio: 2157 is good value based on its Price-To-Sales Ratio (22.3x) compared to the estimated Fair Price-To-Sales Ratio (23x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Innovent Biologics

HK$60.8b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$38.40

7.0%

-15.6%

3SBio

HK$13.2b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.61

-2.3%

-25.8%

United Laboratories International Holdings

HK$18.2b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.02

1.8%

26.7%